Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 13, 2004. The report details a share repurchase transaction executed on September 10, 2004, and updates regarding directors' interests in company shares and employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 430,000 Ordinary shares.
- Purchase Price: 1,153.3023 pence per share.
- Treasury Holdings: 42,873,000 shares held in Treasury following the purchase.
- Shares in Issue: 5,891,612,674 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 430,000 shares, which were subsequently held in Treasury. Additionally, there were minor adjustments in directors' interests due to employee trust distributions and movements in the US Retirement Savings Plan fund:
- Employee Trust: 2,720 Ordinary Shares were transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Plan: The number of Ordinary Share ADRs held by the fund increased from 19,146,649 to 19,181,782 at an average price of $41.50.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 430,000 share repurchase against the stated price of 1,153.3023 pence.
- Confirm the updated total share count (5,891,612,674 in issue) against subsequent filings.
- Review the impact of the 42,873,000 Treasury shares on earnings per share calculations in future reports.
- Check for any further disclosures regarding the directors' interests in the GSK Trust and US Retirement Savings Plan.